Tuesday:
Revenue at $NEM (-1,9%) Nemetschek rose by more than 25% in the third quarter. The company also posted double-digit organic growth. The forecast was confirmed. However, the company’s approach to AI and its own AI applications remains unclear at this point. As a result, shareholders remained skeptical for the time being.
https://www.boerse-global.de/nemetschek-aktie-die-wachstumsziele-stehen-weiter/843616
High uncertainty at $NVDA (-11,46%) NVIDIA regarding its future direction without Jensen Huang. He can, however, envision a comeback. Q3 results also exceeded expectations. Revenue totaled more than $115 billion—5% higher than expected. The gross margin was 71–72%.
Thursday:
The total volume of Anthropic’s IPO $ANT (-6,93%) Anthropic, at $107.3 billion, surpassed SpaceX’s IPO. Anthropic simultaneously became the world’s most valuable company, immediately valued at $2 trillion. Retail investors, in particular, were eager to buy the stock…
https://www.tagesschau.de/wirtschaft/finanzen/anthropic-boersengang-ki-boom-100.html
Friday:
The glyphosate nightmare appears to be $BAYN (+2,77%) Bayer. A court has approved Bayer’s settlement with the plaintiffs. This should bring the drama to a close. Lawsuits are no longer worthwhile; those who do not accept a settlement offer will likely receive nothing. This is because lawsuits alleging missing information on the packaging are no longer possible due to a Supreme Court ruling.